NASDAQ:ITRM Iterum Therapeutics (ITRM) Stock Price, News & Analysis $1.29 +0.08 (+6.61%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Iterum Therapeutics Stock (NASDAQ:ITRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Iterum Therapeutics alerts:Sign Up Key Stats Today's Range$1.24▼$1.3350-Day Range$0.91▼$1.8852-Week Range$0.64▼$2.50Volume1.52 million shsAverage Volume944,201 shsMarket Capitalization$29.29 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More… Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Iterum Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreITRM MarketRank™: Iterum Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 594th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIterum Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Iterum Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Iterum Therapeutics are expected to grow in the coming year, from ($1.19) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iterum Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iterum Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Iterum Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.97% of the float of Iterum Therapeutics has been sold short.Short Interest Ratio / Days to CoverIterum Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iterum Therapeutics has recently decreased by 0.65%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIterum Therapeutics does not currently pay a dividend.Dividend GrowthIterum Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.97% of the float of Iterum Therapeutics has been sold short.Short Interest Ratio / Days to CoverIterum Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iterum Therapeutics has recently decreased by 0.65%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.65 News SentimentIterum Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Iterum Therapeutics this week, compared to 1 article on an average week.Search Interest10 people have searched for ITRM on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of Iterum Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.21% of the stock of Iterum Therapeutics is held by institutions.Read more about Iterum Therapeutics' insider trading history. Receive ITRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ITRM Stock News HeadlinesFDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic PartnershipsOctober 28 at 3:02 PM | finance.yahoo.comIterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsOctober 28 at 5:00 AM | prnewswire.comBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 31, 2024 | Porter & Company (Ad)Iterum Therapeutics PLC trading resumesOctober 26, 2024 | markets.businessinsider.comIterum Therapeutics announces FDA approval of OrlynvahOctober 26, 2024 | markets.businessinsider.comIterum Therapeutics Gets FDA Approval Of Orlynvah For Treatment Of Urinary Tract InfectionsOctober 26, 2024 | markets.businessinsider.comUS FDA approves Iterum's treatment for urinary infectionOctober 26, 2024 | msn.comIterum stock rallies 54% on FDA approval of Orlynvah for UTIsOctober 26, 2024 | msn.comSee More Headlines ITRM Stock Analysis - Frequently Asked Questions How have ITRM shares performed this year? Iterum Therapeutics' stock was trading at $1.97 at the start of the year. Since then, ITRM stock has decreased by 34.5% and is now trading at $1.29. View the best growth stocks for 2024 here. How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics plc (NASDAQ:ITRM) announced its earnings results on Wednesday, August, 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.22. When did Iterum Therapeutics' stock split? Iterum Therapeutics shares reverse split on the morning of Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Iterum Therapeutics IPO? Iterum Therapeutics (ITRM) raised $80 million in an IPO on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. How do I buy shares of Iterum Therapeutics? Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include NVIDIA (NVDA), Onconova Therapeutics (ONTX), Zoom Video Communications (ZM), Tesla (TSLA), Meta Platforms (META), SNDL (SNDL) and Atossa Therapeutics (ATOS). Company Calendar Last Earnings8/14/2024Today10/31/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITRM CUSIPN/A CIK1659323 Webwww.iterumtx.com Phone(531) 669-4820FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+283.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,370,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-113.59% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.48) per share Price / Book-2.72Miscellaneous Outstanding Shares22,706,000Free Float20,617,000Market Cap$29.63 million OptionableNot Optionable Beta2.26 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:ITRM) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.